Division of Rheumatology and Immunology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Scand J Rheumatol. 2010 Mar;39(2):99-108. doi: 10.3109/03009740903449313.
Pregnancy can create a challenge for physicians caring for women with rheumatic diseases. For many women with rheumatoid arthritis (RA), pregnancy can provide a reprieve from long-term joint pain and inflammation, but others will not experience remission and will continue to need medication. Systemic lupus erythematosus (SLE) may remain quiet in some women, but in others may become more aggressive during pregnancy, putting both mother and foetus at risk. Women with limited scleroderma can do remarkably well, but scleroderma renal crises can be difficult to manage. A third of pregnancies in women with antiphospholipid syndrome (APS) may be refractory to our best therapy. In general, active inflammation from rheumatic diseases poses a stronger threat to the well-being of both mother and foetus than many immunosuppressant medications. Therefore, continued immunosuppression with the least risky medications will allow for the most optimal pregnancy outcomes.
妊娠可能会给治疗风湿性疾病女性的医生带来挑战。对于许多类风湿关节炎(RA)患者来说,妊娠可以缓解长期的关节疼痛和炎症,但也有一些患者不会出现缓解,仍需继续药物治疗。系统性红斑狼疮(SLE)在一些女性中可能保持静止,但在另一些女性中可能在妊娠期间变得更加活跃,使母亲和胎儿都面临风险。局限性硬皮病患者可能会恢复得很好,但硬皮病肾危象可能难以治疗。三分之一的抗磷脂抗体综合征(APS)患者的妊娠可能对我们的最佳治疗有抵抗。一般来说,风湿性疾病的炎症活动对母亲和胎儿的健康构成的威胁比许多免疫抑制剂药物都要大。因此,继续使用风险最小的药物进行免疫抑制,将使妊娠结果达到最佳。